First American Trust FSB Purchases 3,413 Shares of AbbVie Inc. $ABBV

First American Trust FSB raised its position in AbbVie Inc. (NYSE:ABBV) by 5.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 62,209 shares of the company’s stock after purchasing an additional 3,413 shares during the period. AbbVie makes up about 1.0% of First American Trust FSB’s investment portfolio, making the stock its 23rd biggest holding. First American Trust FSB’s holdings in AbbVie were worth $14,214,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of ABBV. Brighton Jones LLC increased its position in shares of AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after acquiring an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC increased its position in shares of AbbVie by 72.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after acquiring an additional 3,064 shares in the last quarter. Schnieders Capital Management LLC. increased its position in shares of AbbVie by 5.0% during the second quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock worth $3,056,000 after acquiring an additional 789 shares in the last quarter. Ieq Capital LLC increased its position in shares of AbbVie by 4.6% during the second quarter. Ieq Capital LLC now owns 120,035 shares of the company’s stock worth $22,281,000 after acquiring an additional 5,274 shares in the last quarter. Finally, Worldquant Millennium Advisors LLC increased its position in shares of AbbVie by 117.3% during the second quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company’s stock worth $210,685,000 after acquiring an additional 612,702 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

ABBV has been the subject of several research reports. Barclays initiated coverage on shares of AbbVie in a research report on Thursday, February 19th. They set an “overweight” rating and a $275.00 price objective for the company. DZ Bank raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 30th. Evercore set a $235.00 price objective on shares of AbbVie in a research report on Friday, May 15th. Morgan Stanley increased their price objective on shares of AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. Finally, Royal Bank Of Canada initiated coverage on shares of AbbVie in a research report on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 target price for the company. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $253.43.

AbbVie Trading Down 0.1%

AbbVie stock opened at $225.16 on Thursday. The company has a market cap of $397.82 billion, a P/E ratio of 110.92, a price-to-earnings-growth ratio of 0.69 and a beta of 0.32. AbbVie Inc. has a 1-year low of $181.73 and a 1-year high of $244.81. The company has a fifty day simple moving average of $210.64 and a 200 day simple moving average of $219.09.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. The business had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The firm’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same quarter last year, the firm earned $2.46 earnings per share. On average, equities research analysts forecast that AbbVie Inc. will post 14.3 EPS for the current year.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s migraine drug was cleared for use in migraine attacks on the NHS, a sign of broader adoption potential that could support future sales growth. AbbVie’s migraine drug cleared for migraine attacks on NHS
• Positive Sentiment: Allergan Aesthetics, an AbbVie company, highlighted new consumer research in its aesthetics business, reinforcing ongoing brand visibility and interest in its aesthetics portfolio. Allergan Aesthetics Releases ‘The Aesthetics Evolution: What Consumers Really Want’
• Neutral Sentiment: AbbVie presented at Goldman Sachs’ healthcare conference, which typically provides investors with updates on strategy and pipeline but did not include a major new catalyst in the headline. AbbVie Inc. (ABBV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: AbbVie was mentioned in “final trades” and “below fair value”/discount-stock roundups, which may keep valuation-focused investors interested but are not company-specific operational news. Final trades: AbbVie, Morgan Stanley, Shake Shack and the CBOE
• Negative Sentiment: AbbVie received a Complete Response Letter from the FDA for TrenibotE, its fast-acting neurotoxin candidate. The agency cited manufacturing-related issues and raised no safety or efficacy concerns, but the delay still pushes back a potential new product launch. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE
• Negative Sentiment: AbbVie also terminated its deal with I-Mab to develop a cancer drug, removing a potential pipeline opportunity and signaling a setback in its oncology collaboration strategy. AbbVie terminates deal with I-Mab to develop cancer drug

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.